#MDWD

#MDWD MediWound Provides Corporate Update and Financial Outlook Ahead of the J.P. Morgan Healthcare Conference

www.stocktitan.net/news/MDWD/medi-wound-pro...

0 0 0 0

StockTitan

@stocktitan.net

3 months ago

MediWound Reports New Clinical Data Demonstrating NexoBrid®’s Effectiveness in Preventing Traumatic Tattoos After Abrasion and Blast Injuries MediWound (Nasdaq: MDWD) announced peer-reviewed prospective clinical data showing NexoBrid substantially reduces embedded particles that cause traumatic tattoos after abrasion and blast injuries.In a 15-patient study at Sheba Medical Center, mean pigmented wound area fell from 37.5% post-scrubbing to 2.1% after NexoBrid, a 92.5% reduction. Removal rates were 96% for abrasive injuries and 84% for explosive injuries. Treatments were bedside, well tolerated, and reported no treatment-related adverse events in the early post-procedure period.

#MDWD MediWound Reports New Clinical Data Demonstrating NexoBrid®’s Effectiveness in Preventing Traumatic Tattoos After Abrasion and Blast Injuries

www.stocktitan.net/news/MDWD/medi-wound-rep...

0 0 0 0

StockTitan

@stocktitan.net

3 months ago

MediWound Reports Third Quarter 2025 Financial Results and Provides Corporate Update MediWound (Nasdaq: MDWD) reported third quarter 2025 results and a corporate update on November 20, 2025. Q3 revenue was $5.4M, up 23% year-over-year, with gross profit of $0.9M (16.5%). The company completed commissioning of an expanded NexoBrid manufacturing facility, targeting full operational capacity by year-end 2025 and a sixfold production increase. VALUE Phase III enrollment for EscharEx targets 216 patients across ~40 sites; a pre-specified interim assessment is planned after 65% complete treatment. MediWound raised $30M in equity and held $60M in cash as of Sept 30, 2025. Q3 net loss was $2.7M (EPS -$0.24); Adjusted EBITDA loss was $5.4M.

#MDWD MediWound Reports Third Quarter 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/MDWD/medi-wound-rep...

0 0 0 0

StockTitan

@stocktitan.net

4 months ago

#MDWD MediWound Successfully Completes Commissioning of Expanded GMP Manufacturing Facility for NexoBrid®

www.stocktitan.net/news/MDWD/medi-wound-suc...

0 0 0 0

StockTitan

@stocktitan.net

5 months ago

MediWound Announces $30 Million Registered Direct Offering of Ordinary Shares MediWound (Nasdaq: MDWD), a leader in enzymatic therapeutics for tissue repair, has announced a $30 million registered direct offering of ordinary shares. The company will sell 1,734,105 ordinary shares at $17.30 per share to a prominent U.S.-based mutual fund and healthcare-focused investors.The offering is expected to close around September 30, 2025, with H.C. Wainwright & Co. serving as the exclusive placement agent. The proceeds will support EscharEx's pre-commercial activities, enhance manufacturing capabilities, and fund general corporate purposes. The offering is made through the company's shelf registration statement on Form F-3.

#MDWD MediWound Announces $30 Million Registered Direct Offering of Ordinary Shares

www.stocktitan.net/news/MDWD/medi-wound-ann...

0 0 0 0

StockTitan

@stocktitan.net

5 months ago

MediWound Expands Global Reach with Marketing Approval of NexoBrid® in Australia MediWound (Nasdaq: MDWD) has received marketing authorization from Australia's Therapeutic Goods Administration (TGA) for NexoBrid®, its enzymatic therapy for eschar removal in adult and pediatric burn patients. This approval expands NexoBrid's global presence to 45 countries.The company's exclusive partner, Balance Medical, plans to launch NexoBrid commercially in Q4 2025. MediWound's manufacturing expansion, scheduled for completion by year-end 2025, will support the Australian launch and growing global demand. The approval represents a strategic entry point into the broader Asia-Pacific market.

#MDWD MediWound Expands Global Reach with Marketing Approval of NexoBrid® in Australia

www.stocktitan.net/news/MDWD/medi-wound-exp...

0 0 0 0

StockTitan

@stocktitan.net

6 months ago

36 Scientific Studies Support MediWound's NexoBrid: Major Validation at European Burns Congress MediWound's enzymatic burn therapy NexoBrid to be highlighted in 36 presentations at EBA Congress, showcasing data on pediatric, elderly, and critical burn patients. Sept 3-6 in Berlin.

#MDWD MediWound’s NexoBrid® to be Highlighted in 36 Scientific Presentations at the 21st European Burns Association Congress

www.stocktitan.net/news/MDWD/medi-wound-s-n...

0 0 0 0

StockTitan

@stocktitan.net

7 months ago

MediWound Reports Strong Growth as Global Wound Care Partners Join Clinical Trials Enzymatic therapeutics firm posts $5.7M quarterly revenue, secures Essity and Convatec partnerships for EscharEx trials, and expands NexoBrid manufacturing capacity. See earnings details.

#MDWD MediWound Reports Second Quarter 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/MDWD/medi-wound-rep...

0 0 0 0

StockTitan

@stocktitan.net

7 months ago

New Clinical Data Shows 90% of Unprepared Wounds Fail to Heal: MediWound Study Reveals Phase 2 trial reveals wounds treated with EscharEx were 4.1 times more likely to heal. Study validates wound bed preparation as crucial for venous leg ulcer treatment. See results.

#MDWD MediWound Announces New EscharEx® Phase II Data Demonstrating Strong Link Between Wound Bed Preparation and Wound Closure in Venous Leg Ulcers

www.stocktitan.net/news/MDWD/medi-wound-ann...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

7 months ago

Leading Indicators, Monday August 4, 2025 – Crystal Equity Research

Small-cap stocks with strong volume declines, Mon Aug 4th - #CPHI #PC #MURA #YMAB #WHLC #TTEC #MDWD #BCDA #SBXD - More: crystalequityresearch.com/leading-indi... - #smallcap

0 1 0 0

Nasdaq

@nasdaq.activitypub.awakari.com.ap.brid.gy

9 months ago

www.fool.com/earnings/call-transcript...

#MDWD #7a6c38d9-a7a5-4e5f-9cec-d3dc3896b598 #earningscall-transcripts

Result Details

0 0 0 0

StockTitan

@stocktitan.net

9 months ago

MediWound Expands Global Reach: Major Wound Care Players Join Clinical Trials as Revenue Targets $24M New Phase III trial data coming in 2026, manufacturing capacity set to increase 6x. Strategic partnerships with leading wound care companies advance clinical programs. See financials.

#MDWD MediWound Reports First Quarter 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/MDWD/medi-wound-rep...

0 0 0 0

StockTitan

@stocktitan.net

10 months ago

MediWound Announces Publication of Phase II EscharEx® Data Demonstrating Superiority Over Collagenase in Venous Leg Ulcers MediWound (NASDAQ: MDWD) published a post hoc analysis in Wounds journal comparing their EscharEx® treatment to SANTYL® for venous leg ulcers (VLUs). The analysis, based on Phase II ChronEx trial data, demonstrated superior clinical performance of EscharEx over SANTYL, the only FDA-cleared enzymatic debridement agent currently available.Key findings showed that 63% of EscharEx patients achieved complete debridement at 2 weeks versus 0% in the SANTYL group. The median time to debridement was 9 days for EscharEx, while SANTYL did not achieve this milestone. Wound Bed Preparation was achieved by 50% of EscharEx patients in 2 weeks compared to 0% with SANTYL. Notably, wound closure rates were 33% for EscharEx versus 25% for SANTYL, with significantly faster mean time to closure (48 days vs. 76 days). Both treatments showed similar safety profiles, though deep wound infection rates were lower in the EscharEx group (11% vs. 38%).

#MDWD MediWound Announces Publication of Phase II EscharEx® Data Demonstrating Superiority Over Collagenase in Venous Leg Ulcers

www.stocktitan.net/news/MDWD/medi-wound-ann...

0 0 0 0

StockTitan

@stocktitan.net

11 months ago

MediWound Delivers Record Revenue Growth: NexoBrid Sales Soar 42% Amid Major Funding Wins MediWound secures €16.5M EU grant and $25M investment while NexoBrid adoption accelerates. Strong product momentum and expanded partnerships fuel 2025 growth outlook.

#MDWD MediWound Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

www.stocktitan.net/news/MDWD/medi-wound-rep...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Can NexoBrid Transform Pediatric Burn Care? Phase III Results Show Superiority Study confirms NexoBrid's effectiveness as a non-surgical solution for pediatric burn patients, supporting recent U.S. and E.U. approvals and addressing 30% of burn cases.

#MDWD MediWound Announces Phase III CIDS Publication on NexoBrid® for Pediatric Burn Care

www.stocktitan.net/news/MDWD/medi-wound-ann...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

EscharEx Clinical Trial: MediWound's Groundbreaking Solution for $375M Venous Ulcer Market MediWound initiates pivotal VALUE trial across 40 sites, testing EscharEx for venous leg ulcers. Strategic partnerships boost development of first new treatment in decades.

#MDWD MediWound Initiates the VALUE Global Phase III Pivotal Trial of EscharEx® for Treatment of Venous Leg Ulcers

www.stocktitan.net/news/MDWD/medi-wound-ini...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

#MDWD MediWound Reports Third Quarter 2024 Financial Results and Provides Company Update

www.stocktitan.net/news/MDWD/medi-wound-rep...

0 0 0 0

Elsie the Fall WeatherFox

@weatherfox64.bsky.social

1 year ago

RadarScope screenshot of a line of thunderstorms out near Dulles airport and western parts of the DC metro area. The storms are moving east and about 30 minutes out from me.

Oh hello cold front and storms.

Time to head home before they overtake me! Hopefully there will be some nice storms tonight.

KLWX 17:21 EDT Reflectivity #mdwd #vawx #dcwx

6 0 3 0

Posts tagged #MDWD